PSGL-1

PSGL-1 Informations sur la molécule

Nom anglais	P-selectin glycoprotein ligand-1	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	4	Alias de la cible	P-selectin glycoprotein ligand 1，PSGL-1，SELPLG，Selectin P Ligand，Cutaneous Lymphocyte-Associated Associated Antigen，CD162 Antigen，CD162，PSGL1，CLA
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	P-selectin glycoprotein ligand-1
Alias de la cible	P-selectin glycoprotein ligand 1，PSGL-1，SELPLG，Selectin P Ligand，Cutaneous Lymphocyte-Associated Associated Antigen，CD162 Antigen，CD162，PSGL1，CLA
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	4
Phase de R&D la plus avancée	Phase 2 Clinical

PSGL-1 Liste de produits

Attribut
Protein (2)
Bibliothèque de produits
En ligne (2)
Espèces
Human (2)
Étiquette
His Tag (1)His Tag & Avi Tag (1)
Marqueur
Unconjugated (1)Biotin-labeled (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
PS1-H52H9	Human	HEK293	Human PSGL-1 / CD162 Protein, His Tag				Ajouter au panier
PS1-H82E4	Human	HEK293	Biotinylated Human PSGL-1 / CD162 Protein, His,Avitag™				Ajouter au panier

Quantité totale2

PSGL-1Contexte de la molécule

P-selectin glycoprotein ligand 1 (PSGL-1) is also known as Selectin P ligand (SELPLG), CD antigen CD162. PSGL-1 is disulfide-linked homodimer which is the high affinitycounter-receptor for P-selectin on expressed on activated endothelial cells and platelets. PSGL-1 / SELPLG interacts with P-, E- and L-selectins, through their lectin/EGF domains, is required for promoting recruitment and rolling of leukocytes. These interactions require sialyl Lewis X glycan modification but there is a differing dependence for tyrosine sulfations. Dimerization appears not to be required for P-selectin/SELP binding. PSGL-1 can interact with SNX20, MSN and SYK. PSGL-1 / SELPLG mediate the activation of SYK by SELPLG.

PSGL-1Alias de la molécule

PSGL1,CD162,SELPLG,Selectin P ligand

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Cepeprubart	SelK-2	Phase 2 Clinical	Selexys	Asthma; Pulmonary Disease, Chronic Obstructive; Venous Thromboembolism	Details
Leiolizumab	AbGn 168H2; AbGn-268; AbGn-168H2; ALTB-268	Phase 2 Clinical	Altrubio Inc	Arthritis, Psoriatic; Colitis, Ulcerative	Details
Neihulizumab	AbGn-168; AbGn-168H; ALTB-168	Phase 1 Clinical	Altrubio Inc	Arthritis, Psoriatic; Colitis, Ulcerative; Graft vs Host Disease; Plaque psoriasis; Psoriasis	Details
SSGJ-617	SSGJ-617; SSGJ617; 61X; VTX-0811; 617	Phase 1 Clinical	Verseau Therapeutics Inc	Solid tumours	Details